• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Etoposide treatment adjunctive to immunosuppressants for critically ill COVID-19 patients.

作者信息

M Montero-Baladía, L Buzón, I Astigarraga, P Delgado, E Iglesias, F Callejo, M López-Veloso, J Minguito, M Fernández-Regueras, M Ubeira, G Hermida

机构信息

Critical Care, Hospital Universitario de Burgos, Avenida Islas Baleares s/n, 09006 Burgos, Spain.

Internal Medicine and Infectious Diseases, Hospital Universitario de Burgos, Avenida Islas Baleares s/n, 09006 Burgos, Spain.

出版信息

J Infect. 2020 Sep;81(3):452-482. doi: 10.1016/j.jinf.2020.06.006. Epub 2020 Jun 21.

DOI:10.1016/j.jinf.2020.06.006
PMID:32579985
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7306195/
Abstract
摘要

相似文献

1
Etoposide treatment adjunctive to immunosuppressants for critically ill COVID-19 patients.依托泊苷作为免疫抑制剂的辅助治疗用于危重症COVID-19患者。
J Infect. 2020 Sep;81(3):452-482. doi: 10.1016/j.jinf.2020.06.006. Epub 2020 Jun 21.
2
Reply to the letter by Gaetano Loscocco, Secondary hemophagocytic lymphohistiocytosis, HScore and COVID-19.对盖埃塔诺·洛斯科科来信的回复，继发性噬血细胞性淋巴组织细胞增生症、HScore与2019冠状病毒病
Int J Hematol. 2020 Jul;112(1):127. doi: 10.1007/s12185-020-02896-9. Epub 2020 May 28.
3
Possible role of low-dose etoposide therapy for hemophagocytic lymphohistiocytosis by COVID-19.低剂量依托泊苷疗法对新型冠状病毒肺炎相关噬血细胞性淋巴组织细胞增生症的潜在作用
Int J Hematol. 2020 Jul;112(1):122-124. doi: 10.1007/s12185-020-02888-9. Epub 2020 May 12.
4
Secondary hemophagocytic lymphohistiocytosis, HScore and COVID-19.继发性噬血细胞性淋巴组织细胞增生症、HScore与2019冠状病毒病
Int J Hematol. 2020 Jul;112(1):125-126. doi: 10.1007/s12185-020-02895-w. Epub 2020 May 30.
5
Dexamethasone: A boon for critically ill COVID-19 patients?地塞米松：对危重症COVID-19患者是福音吗？
Travel Med Infect Dis. 2020 Sep-Oct;37:101844. doi: 10.1016/j.tmaid.2020.101844. Epub 2020 Aug 10.
6
Inhaled nitric oxide for critically ill Covid-19 patients: a prospective study.吸入一氧化氮治疗重症新冠患者：一项前瞻性研究。
Crit Care. 2020 Nov 12;24(1):645. doi: 10.1186/s13054-020-03371-x.
7
Hydroxychloroquine pharmacokinetic in COVID-19 critically ill patients: an observational cohort study.羟氯喹在新冠肺炎危重症患者中的药代动力学：一项观察性队列研究。
Intensive Care Med. 2020 Sep;46(9):1772-1773. doi: 10.1007/s00134-020-06142-y. Epub 2020 Jun 8.
8
Etoposide-based therapy for severe forms of COVID-19.依托泊苷为基础的疗法治疗严重 COVID-19 。
Med Hypotheses. 2020 Sep;142:109826. doi: 10.1016/j.mehy.2020.109826. Epub 2020 May 8.
9
Venous Thrombosis Among Critically Ill Patients With Coronavirus Disease 2019 (COVID-19).新冠肺炎危重症患者的静脉血栓栓塞症。
JAMA Netw Open. 2020 May 1;3(5):e2010478. doi: 10.1001/jamanetworkopen.2020.10478.
10
Potential Treatments for COVID-19 Related Cytokine Storm - Beyond Corticosteroids.新冠病毒相关细胞因子风暴的潜在治疗方法——超越皮质类固醇
Front Immunol. 2020 Jun 16;11:1445. doi: 10.3389/fimmu.2020.01445. eCollection 2020.

引用本文的文献

1
Advances in attractive therapeutic approach for macrophage activation syndrome in COVID-19.COVID-19 中巨噬细胞活化综合征有吸引力的治疗方法进展。
Front Immunol. 2023 Jul 6;14:1200289. doi: 10.3389/fimmu.2023.1200289. eCollection 2023.
2
Integrated Analgesic Care in the Current Human Monkeypox Outbreak: Perspectives on an Integrated and Holistic Approach Combining Old Allies with Innovative Technologies.当前人类猴痘疫情中的综合止痛治疗：结合旧盟友与创新技术的综合与整体方法的观点。
Medicina (Kaunas). 2022 Oct 15;58(10):1454. doi: 10.3390/medicina58101454.
3
Endophytic Fungal Terpenoids: Natural Role and Bioactivities.

本文引用的文献

1
Pathogenic T-cells and inflammatory monocytes incite inflammatory storms in severe COVID-19 patients.致病性T细胞和炎性单核细胞在重症COVID-19患者中引发炎症风暴。
Natl Sci Rev. 2020 Jun;7(6):998-1002. doi: 10.1093/nsr/nwaa041. Epub 2020 Mar 13.
2
Early Short-Course Corticosteroids in Hospitalized Patients With COVID-19.COVID-19 住院患者的早期短程皮质类固醇治疗。
Clin Infect Dis. 2020 Nov 19;71(16):2114-2120. doi: 10.1093/cid/ciaa601.
3
Rationale for Prolonged Corticosteroid Treatment in the Acute Respiratory Distress Syndrome Caused by Coronavirus Disease 2019.
内生真菌萜类化合物：天然作用与生物活性。
Microorganisms. 2022 Feb 1;10(2):339. doi: 10.3390/microorganisms10020339.
4
Drug repurposing for coronavirus (SARS-CoV-2) based on gene co-expression network analysis.基于基因共表达网络分析的冠状病毒（SARS-CoV-2）药物再利用。
Sci Rep. 2021 Nov 8;11(1):21872. doi: 10.1038/s41598-021-01410-3.
5
Case Report: Successful Treatment of Five Critically Ill Coronavirus Disease 2019 Patients Using Combination Therapy With Etoposide and Corticosteroids.病例报告：使用依托泊苷和皮质类固醇联合疗法成功治疗5例重症2019冠状病毒病患者
Front Med (Lausanne). 2021 Sep 23;8:718641. doi: 10.3389/fmed.2021.718641. eCollection 2021.
6
Haemophagocytic lymphohistiocytosis in pregnancy: a pertinent case during the COVID-19 pandemic.妊娠合并噬血细胞性淋巴组织细胞增生症：COVID-19 大流行期间的一个相关病例。
BMJ Case Rep. 2021 Sep 17;14(9):e244716. doi: 10.1136/bcr-2021-244716.
7
Response.反应
Chest. 2021 Apr;159(4):1679. doi: 10.1016/j.chest.2020.11.035. Epub 2021 Apr 6.
8
Etoposide for Cytokine Storm Because of Coronavirus Disease 2019.依托泊苷用于治疗2019冠状病毒病引起的细胞因子风暴
Chest. 2021 Apr;159(4):1678-1679. doi: 10.1016/j.chest.2020.10.090. Epub 2021 Apr 6.
9
Benefits of early aggressive immunomodulatory therapy (tocilizumab and methylprednisolone) in COVID-19: Single center cohort study of 685 patients.早期积极免疫调节治疗（托珠单抗和甲泼尼龙）对COVID-19的益处：685例患者的单中心队列研究
J Transl Autoimmun. 2021;4:100086. doi: 10.1016/j.jtauto.2021.100086. Epub 2021 Feb 12.
10
Immune Dysfunction and Multiple Treatment Modalities for the SARS-CoV-2 Pandemic: Races of Uncontrolled Running Sweat?SARS-CoV-2大流行中的免疫功能障碍与多种治疗方式：失控的赛跑汗水之种种？
Biology (Basel). 2020 Aug 24;9(9):243. doi: 10.3390/biology9090243.
2019冠状病毒病所致急性呼吸窘迫综合征长期使用皮质类固醇治疗的理论依据
Crit Care Explor. 2020 Apr 29;2(4):e0111. doi: 10.1097/CCE.0000000000000111. eCollection 2020 Apr.
4
Should we stimulate or suppress immune responses in COVID-19? Cytokine and anti-cytokine interventions.我们应该在 COVID-19 中刺激还是抑制免疫反应？细胞因子和抗细胞因子干预。
Autoimmun Rev. 2020 Jul;19(7):102567. doi: 10.1016/j.autrev.2020.102567. Epub 2020 May 4.
5
The many faces of the anti-COVID immune response.抗新冠病毒免疫反应的多面性。
J Exp Med. 2020 Jun 1;217(6). doi: 10.1084/jem.20200678.
6
Baricitinib therapy in COVID-19: A pilot study on safety and clinical impact.巴瑞替尼治疗新冠肺炎：一项关于安全性和临床影响的初步研究。
J Infect. 2020 Aug;81(2):318-356. doi: 10.1016/j.jinf.2020.04.017. Epub 2020 Apr 23.
7
The pathogenesis and treatment of the `Cytokine Storm' in COVID-19.新型冠状病毒病中“细胞因子风暴”的发病机制与治疗。
J Infect. 2020 Jun;80(6):607-613. doi: 10.1016/j.jinf.2020.03.037. Epub 2020 Apr 10.
8
COVID-19: consider cytokine storm syndromes and immunosuppression.2019冠状病毒病：考虑细胞因子风暴综合征和免疫抑制。
Lancet. 2020 Mar 28;395(10229):1033-1034. doi: 10.1016/S0140-6736(20)30628-0. Epub 2020 Mar 16.
9
Recommendations for the management of hemophagocytic lymphohistiocytosis in adults.成人噬血细胞性淋巴组织细胞增生症的治疗建议。
Blood. 2019 Jun 6;133(23):2465-2477. doi: 10.1182/blood.2018894618. Epub 2019 Apr 16.
10
Recommendations for the Use of Etoposide-Based Therapy and Bone Marrow Transplantation for the Treatment of HLH: Consensus Statements by the HLH Steering Committee of the Histiocyte Society.HLH 治疗中依托泊苷治疗和骨髓移植的建议：组织细胞学会 HLH 指导委员会的共识声明。
J Allergy Clin Immunol Pract. 2018 Sep-Oct;6(5):1508-1517. doi: 10.1016/j.jaip.2018.05.031. Epub 2018 Jul 4.